Slide 1: Year-End 2025 Earnings Conference Call
Year-End 2025 Earnings Conference Call 2/26/2026 Teleflex Incorporated Exhibit 99.2
Slide 2: Conference Call Logistics
The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on February 26, 2026 either on the Teleflex website or by telephone. The call can be accessed by dialing
Slide 3: Today's Speakers
Today’s Speakers TELEFLEX EARNINGS CONFERENCE CALL 2/26/2026 Lawrence Keusch VP, Investor Relations and Strategy Development Stuart Randle Interim President and CEO John Deren Executive VP and CFO
Slide 4: Additional Notes
TELEFLEX EARNINGS CONFERENCE CALL 2/26/20264 Additional Notes This document contains certain highlights with respect to our year end 2025 results and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended D
Slide 5: Executive Overview
Stuart Randle Interim President and CEO Executive Overview
Slide 6: 2027 Establishes Our Normalized, Steady-State Financial Profile
– We have identified a number of transient factors related to our Strategic Divestitures that will impact 2026 results, including: – We expect 2027 results to provide a more representative view of our standalone, steady-state financial profile 2026 will be a transition year for Teleflex as we antici
Slide 7: 2025 Performance Summary
2025 Performance Summary ◦ Pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50% ◦ Adjusted diluted EPS from continuing operations guidance of $6.25 to $6.55 ◦ 2H'25 pro forma adjusted constant currency revenue grew 4.7% year-over-year ◦ 2025 adjusted gross margin of 6
Slide 8: 2H'25 Global Product Commentary of Continuing Operations
2H'25 Global Product Commentary of Continuing Operations TELEFLEX EARNINGS CONFERENCE CALL 2/26/20268 Vascular Interventional Sales ($M) Commentary • In 2H'25 growth was primarily driven by our central access, hemostatic, and atomization products Surgical • Excluding the impact of the Vascular Inter
Slide 9: Financial Overview
John Deren Executive VP and CFO Financial Overview
Slide 10: 2025 Financial Review of Continuing Operations
2025 Financial Review of Continuing Operations TELEFLEX EARNINGS CONFERENCE CALL 2/26/202610 Note: See appendices for reconciliations of non-GAAP financial information. SG&A Expense (% of Sales) Gross Margin R&D Expense (% of Sales) Operating Margin Earnings per Share ◦ negative impact of tariffs ◦
Slide 11: 2026 Financial Guidance
11 Revenue ◦ 2026 GAAP revenue from continuing operations growth in the range of 14.4% to 15.4% year-over-year ◦ 2026 pro forma adjusted constant currency revenue growth in the range of 4.5% to 5.5% Earnings Per Share ◦ 2026 GAAP EPS from continuing operations in the range of $2.90 to $3.20 ◦ 2026 A
Slide 12: 2026 Guidance Considerations
2026 Guidance Considerations 12 Pro Forma Adj. CC Revenue Growth ◦ 4.5% to 5.5% pro forma adjusted constant currency revenue growth for 2026 Adjusted Earnings Per Share ◦ 2026 adjusted EPS from continuing operations in the range of $6.25 to $6.55 ◦ Excludes foreign exchange, Italian payback matter,
Slide 13: 2026 Financial Guidance – Future Opportunities
13 Adjusted Operating Margin ◦ $90m stranded costs impacting 2026 adjusted operating margin Debt Paydown ◦ Intend to pay down ~$800 million in debt, including debt associated with the Vascular Intervention acquisition, funded with net proceeds from the sale transactions Share Repurchase ◦ $1 billion
Slide 14: 2026 Financial Guidance of Continuing Operations Summary
2026 Financial Guidance of Continuing Operations Summary TELEFLEX EARNINGS CONFERENCE CALL 2/26/202614 2026 Guidance Low High GAAP Revenue Growth 14.4% 15.4% Impact of Vascular Intervention Pro Forma 10.0% 10.0% Impact of Discontinued Product (0.7)% (0.7)% Impact of Italian Payback Measure (0.5)% (0
Slide 15: Forecasted 2026 Adjusted Constant Currency Revenue Growth Reconciliation
Forecasted 2026 Adjusted Constant Currency Revenue Growth From Continuing Operations Reconciliation TELEFLEX EARNINGS CONFERENCE CALL 2/26/202615 2026 Guidance 2025 2026 Guidance Low High GAAP revenue $1,992.7 $2,280 $2,300 % growth 14.4% 15.4% Vascular Intervention pro forma adjustment 199.0 — — Di
Slide 16: Key Takeaways
TELEFLEX EARNINGS CONFERENCE CALL 2/26/202616 Key Takeaways Teleflex is in the midst of a transformation that • optimizes our portfolio • creates a more focused medical technologies leader • and positions our company for meaningful value creation opportunities going forward. It is energizing to see
Slide 17: Thank You!
TELEFLEX EARNINGS CONFERENCE CALL 2/26/202617 Thank You!
Slide 18: Appendices
Appendices Empowering the future of healthear
Slide 19: Non-GAAP Adjustments
The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: Adjusted revenue. This non-GAAP measure is based upon net revenues,
Slide 20: Adjusted diluted earnings per share definition
Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment
Slide 21: Explanation of non-GAAP adjustments
The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring and optimization charges - Restructuring and optimization charges includ
Slide 22: Pension termination and European medical device regulation adjustments
Pension termination and related charges - These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental expenses including certain charges stemming from the l
Slide 23: Appendix A1 – Pro Forma Adjusted Revenue by Global Product Category
Appendix A1 – Pro Forma Adjusted Revenue by Global Product Category (Dollars in millions) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202623 FY 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Vascular 917.7 240.2 232.5 225.9 219.1 Interventional 647.8 217.9 215.9 113.8 100.2 Surgical 418.2 110.9 109.5 102.8 95.0 Ot
Slide 24: Appendix A2 – Reconciliation of Pro Forma Adjusted Constant Currency Revenue Growth
Appendix A2 – Reconciliation of Pro Forma Adjusted Constant Currency Revenue Growth by Global Product Category TELEFLEX EARNINGS CONFERENCE CALL 2/26/202624 2H 2025 Q4 2025 Q3 2025 Reported Revenue Growth Currency Impact Adjustment Impact Pro Forma Adjusted Constant Currency Revenue Growth Reported
Slide 25: Appendix A3 – Reconciliation of Revenues
Appendix A3 – Reconciliation of Revenues (Dollars in millions) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202625 December 31, 2025 GAAP revenue including discontinued operations $3,297.0 Discontinued operations (1,304.3) Continuing operations 1,992.7 Italian payback measure adjustment (9.0) Continuing o
Slide 26: Appendix B1 – Reconciliation of Consolidated Statement of Income Items
Appendix B1 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202626 Three Months Ended December 31, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) (Loss) Income before income taxes Income t
Slide 27: Three Months Ended December 31, 2024 Reconciliation
Three Months Ended December 31, 2024 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $442.0 60.8% 40.3% 6.6% 11.9% $35.5 -$0.4 (1.1)% $0.77 Adjustments
Slide 28: Appendix B3 – Reconciliation of Consolidated Statement of Income Items
Appendix B3 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202628 Year Ended December 31, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effe
Slide 29: Year Ended December 31, 2024 Reconciliation
Year Ended December 31, 2024 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $1,699.5 61.0% 47.5% 6.4% 6.1% $26.3 $(30.9) (117.5)% $1.21 Adjustments Res
Slide 30: Reconciliation footnotes
TELEFLEX EARNINGS CONFERENCE CALL 2/26/202630 A. Restructuring and optimization charges – For the three months ended December 31, 2025, pre-tax restructuring charges were $20.2 million, restructuring related charges were $3.5 million, and product optimization charges were $0.6 million. For the three
Slide 31: Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation
Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation TELEFLEX EARNINGS CONFERENCE CALL 2/26/202631 Forecasted GAAP Operating Margin 10.5% Estimated restructuring and optimization items 2.0% Estimated acquisition, integration and divestiture related items 1.9% Estimated other items (1.1)%
Slide 32: Appendix D - Reconciliation of Forecasted 2026 Adjusted EPS Guidance
Appendix D - Reconciliation of Forecasted 2026 Adjusted Earnings Per Share Guidance TELEFLEX EARNINGS CONFERENCE CALL 2/26/202632 Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $2.90 $3.20 Restructuring and optimization items, net of tax $0.81 $0.81 Acquisition, integ
Slide 33: Appendix E1 – Supplemental Historical Reconciliation
Appendix E1 – Supplemental Historical Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202633 Three Months Ended September 28, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) (Loss) Income bef
Slide 34: Three Months Ended June 29, 2025 Reconciliation
Three Months Ended June 29, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $442.5 60.1% 31.1% 6.0% 20.6% $70.7 $2.5 3.5% $1.54 Adjustments Restruc
Slide 35: Appendix E3 – Supplemental Historical Reconciliation
Appendix E3 – Supplemental Historical Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202635 Three Months Ended March 30, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income
Slide 36: Reconciliation footnotes
TELEFLEX EARNINGS CONFERENCE CALL 2/26/202636 A. Restructuring and optimization charges – For the three months ended September 28, 2025, pre-tax restructuring charges were $1.6 million and restructuring related charges were $3.3 million. For the three months ended June 29, 2025, pre-tax restructurin